CONTEMPORARY APPROACHES TO LEVOTHYROXINE THERAPY AFTER SURGERY IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER
https://doi.org/10.17650/2222-1468-2013-0-2-5-8
Abstract
Levothyroxine therapy with purpose to suppress thyroid stimulating hormone (TSH) after surgery in patients with well-differentiated thyroid cancer is implemented since 1937. Accumulated results of levothyroxine suppressive therapy (LST) application are attesting its heterogeneous efficacy in various risk groups of tumor recurrence: low, medium and high. Similar risk groups are emphasized towards adverse effect risk due to LST. The more intensivity and duration of TSH suppression the higher risk of adverse effects. First, they include osteopenia or osteoporosis and atrial fibrillation. Contemporary approaches to intensivity and duration of LTS are based on accounting of its potential efficiency into various clinical risk groups of tumor recurrence as well as adverse effects risk groups.
About the Authors
P. O. Rumyantsev
Endocrinology Research Center, Moscow
Russian Federation
Russian Federation
S. V. Korenev
Medical institute, Immanuel Kant Baltic Federal University, Kaliningrad
Russian Federation
Russian Federation
U. V. Rumyantseva
Endocrinology Research Center, Moscow
Russian Federation
Russian Federation
References
1. Vassart G., Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992;13(3):596–611.
2. Hoelting T., Tezelman S., Siperstein A.E. et al. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid 1995;5(1):35–40.
3. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008;93(4):1167–9.
4. Pacini F. Why do we need guidelines for differentiated thyroid cancer? Thyroid 2006;16(2):103–4.
5. Cooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109–42.
6. Am dur R.J., Mazzaferri E.L. Essentials of thyroid cancer managenent. New-York: Springer, 2005.
7. Mazzaferri E.L. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9(5):421–7.
8. Burmeister L.A., Goumaz M.O., Mariash C.N., Oppenheimer J.H. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992;75(2):344–50.
9. Sugitani I., Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011;150(6):1250–7.
10. Biondi B., Filetti S., Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005;1(1):32–40.
11. Mazzaferri E.L., Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63.
12. Pujol P., Daures J.P., Nsakala N. et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81(12):4318–23.
13. Jonklaas J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.
14. Hovens G .C., Stokkel M.P., Kievit J. et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92(7):2610–5.
Review
For citations:
Rumyantsev P.O., Korenev S.V., Rumyantseva U.V. CONTEMPORARY APPROACHES TO LEVOTHYROXINE THERAPY AFTER SURGERY IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER. Head and Neck Tumors (HNT). 2013;(2):5-8. (In Russ.) https://doi.org/10.17650/2222-1468-2013-0-2-5-8
Views:
1166
Email this article 